Recombinant sulfydryl streptavidin freeze-dried powder, solution and preparation method and application thereof

By freeze-drying using a mixed solution of trehalose, TCEP and HEPES during the lyophilization process, the problem of recombinant thiol streptavidin forming unstable aggregates is solved, its stability and resolubility are improved, and biotin is ensured Combined with the stability of capabilities, it is suitable for large-scale production.

CN118978579AInactive Publication Date: 2024-11-19HANGZHOU NEUROPEPTIDE BIOLOGICAL SCI & TECH INC LTD (NUPTEC)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411466225.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-21
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Recombinant thiol streptavidin is prone to form unstable octamers or higher polymers after the lyophilization process, resulting in reduced biotin binding capacity and storage stability problems.

Method used

The mixed solution of trehalose, TCEP and HEPES was used for freeze-drying, and the pH value was controlled at 6.5-7.5 to form a phosphoric acid-TCEP complex to stabilize the reduction ability of TCEP. The lyophilized powder was prepared by vacuum freeze-drying technology to ensure the thiol of the protein. Stability and resoluble.

Benefits of technology

The stability and resolubility of recombinant thiol streptavidin is improved, ensuring its stability in binding ability to biotin after simulated summer transportation, and is suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978579A_ABST
    Figure CN118978579A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine preparations, in particular to recombinant sulfydryl-streptavidin freeze-dried powder capable of being used for separating, detecting and marking biological molecules and a preparation method of the recombinant sulfydryl-streptavidin freeze-dried powder. The recombinant sulfydryl-streptavidin freeze-dried powder contains TCEP, HEPES and trehalose, is excellent in resolubility, extremely few in high polymer formation, free of removal of a protective agent in subsequent application, capable of directly performing downstream coupling reaction, simplified in use steps, low in processing cost and suitable for large-scale production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of protein freeze-dried powder preparation, and in particular to a recombinant thiol streptavidin freeze-dried powder, a solution preparation method, and the preparation method and application thereof in separation, detection and labeling of biological molecules. Background Art

[0002] Streptavidin is a protein with a high affinity for biotin and is commonly used for the separation, detection and labeling of biological molecules. Recombinant thiol streptavidin is a genetically engineered streptavidin with cysteine ​​added to the C-terminus of the protein. It not only retains the extremely high affinity with biotin, but also the thiol functional group can specifically form a covalent bond with the reactive groups on the carrier (such as maleimide groups). This directional coupling ensures that the active site of streptavidin is exposed and can efficiently bind to biotin, thereby improving the binding efficiency and stability of the coupling reaction and avoiding the side reactions and product heterogeneity problems caused by random coupling.

[0003] Streptavidin itself is a tetrameric structural protein. Since thiol is a highly reactive group, it is easy to undergo redox reactions with other thiol groups to form disulfide bonds. Therefore, in the actual production and use process, recombinant thiol streptavidin is easy to form octamers or even higher polymers, which leads to a series of problems such as the spatial position of the biotin binding site is shielded, the non-specific binding sites on the protein surface increase, the stability of long-term storage decreases, and the coupling efficiency decreases. Before using recombinant thiol streptavidin, it is generally necessary to treat it with a high concentration of reducing agent such as dithiothreitol (DTT) or tris (2-carboxyethyl) phosphine hydrochloride (TCEP) to restore it to a tetrameric form. However, after such treatment, the reducing agent needs to be removed by dialysis or gel filtration to avoid its interference with the coupling reaction. Summary of the invention

[0004] The present invention provides a method for preparing recombinant thiol streptavidin. The recombinant thiol streptavidin lyophilized powder prepared by the preparation method can ensure the stability of the thiol group of the protein, is easy to store and transport, and has good resolubility, which solves the problem that the recombinant thiol streptavidin is easy to form octamers or even higher polymers after the lyophilization process, and its own physical and chemical properties are not stable enough, the resolubility decreases after the summer transportation process, and the binding ability with biotin decreases. The solution prepared after the recombinant thiol streptavidin is re-dissolved is used for activity detection, and the results show that the ability of the protein to bind to biotin is very stable, and after simulating the summer transportation process, its activity is not significantly different from the initial state.

[0005] As a first aspect of the present invention, the present invention provides a method for preparing a recombinant thiol streptavidin lyophilized powder, comprising the following steps: 1) Add trehalose to a mixed solution of recombinant thiol streptavidin stock solution, TCEP, and HEPES, and control the pH value of the mixed solution to be 6.5-7.5; the concentration of the recombinant thiol streptavidin is 5-10 mg / ml, the concentration of TCEP is 20 mM, the concentration of HEPES is 20 mM, and the mass fraction of trehalose is 1.5%; wherein the existing phosphate buffer system will interact with TCEP to form a phosphate-TCEP complex, thereby reducing the effective concentration of TCEP, and the HEPES buffer system of the present invention can ensure the reducing ability and stability of TCEP. The pH value of the recombinant thiol streptavidin stock solution is controlled between 6.5-7.5 to ensure its optimal reactivity with the downstream coupling group.

[0006] 2) Freeze-drying the mixed liquid; freeze-drying includes three stages: pre-freezing, sublimation drying and analytical drying, and the specific operating conditions are as follows: the temperature of the pre-freezing stage is set at -50~-20℃, and the holding time is 60 to 300 minutes; the temperature of the sublimation drying stage is set at -40~10℃, the holding time is 300 to 1500 minutes, and the vacuum degree is 0 to 0.5 mbar; the temperature of the analytical drying stage is set at -20~20℃, the holding time is 60 to 600 minutes, and the vacuum degree is 0 to 0.01 mbar.

[0007] In certain embodiments of the present invention, it takes 20 to 60 minutes to adjust from room temperature to the target temperature of the pre-freezing stage, 20 to 60 minutes to adjust to the target temperature of the sublimation drying stage, and 30 to 300 minutes to adjust to the target temperature of the analytical drying stage.

[0008] As a second aspect of the present invention, the present invention provides a recombinant thiol-streptavidin lyophilized powder prepared by the above method.

[0009] As a third aspect of the present invention, the present invention further provides a solution based on the recombinant thiol-streptavidin lyophilized powder, which comprises the above-mentioned recombinant thiol-streptavidin lyophilized powder and a solvent.

[0010] Furthermore, the solvent in the above solution is pure water, and the usage ratio of pure water to the recombinant thiol streptavidin lyophilized powder is 1 mL:10 mg; Finally, the present invention also provides the use of recombinant thiol streptavidin lyophilized powder in the separation, detection and labeling of biological molecules. Specifically, the above-mentioned lyophilized powder and its solution can be widely used in biosensors, protein purification, immunoassay, molecular biology, cell biology, nanotechnology, drug delivery and material science and other fields.

[0011] The beneficial effects of the present invention are as follows: the present invention utilizes vacuum freeze-drying technology, and after experimental exploration of technical parameters, successfully prepares recombinant thiol streptavidin into a freeze-dried powder dosage form, thereby improving the solubility and stability of the protein. At the same time, the freeze-drying process and preparation method provided by the present invention are simple and feasible, with mild conditions, good reproducibility, strong controllability, and suitable for large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 This is the freeze-drying curve of recombinant thiol streptavidin.

[0013] Figure 2 The results are for investigating the clarity of solutions of any three samples in Example 1.

[0014] Figure 3 (a) is a graph showing the protein purity test results of Example 1. Figure 3 (b) in the figure is the protein purity detection data diagram.

[0015] Figure 4 (a) is a tetramer detection result diagram of Example 1, Figure 4 (b) in the figure shows the tetramer percentage data results.

[0016] Figure 5 The results of the protein activity test in Example 1 are shown in FIG.

[0017] Figure 6 The results are for investigating the clarity of solutions of any three samples of Comparative Example 1.

[0018] Figure 7 (a) is a graph showing the protein purity test results of Comparative Example 1. Figure 7 (b) in the figure is the protein purity detection data diagram.

[0019] Figure 8 (a) is the tetramer detection result diagram of Comparative Example 1, Figure 8 (b) in the figure shows the tetramer percentage data results.

[0020] Fig. 9 This is the result of investigating the protein activity of Comparative Example 1. DETAILED DESCRIPTION

[0021] The present invention is described below by specific examples to make the technical solution of the present invention easier to understand and grasp, but the present invention is not limited thereto. The methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the main purpose of the present invention. The reagents and materials, such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), can be obtained from commercial sources unless otherwise specified.

[0022] Some of the packaging materials and containers mentioned or used in the present invention are as follows: the vial is a medium-borosilicate glass tube injection bottle; the rubber stopper is a chlorobutyl rubber stopper for freeze-drying injection; and the aluminum cap is an aluminum-plastic composite cap for antibiotic bottles.

[0023] Example 1 Add recombinant thiol streptavidin stock solution to the vial, so that each vial contains 10 mg of core streptavidin. The concentration of recombinant thiol streptavidin in the stock solution is 10 mg / mL, and the concentrations of HEPES and TCEP are both 20 mM. Then add the prepared trehalose mother solution, so that the final concentration of trehalose is 1.5%. Gently shake the vial to mix the above mixed solution thoroughly.

[0024] The freeze drying procedure is performed according to the pre-freezing, sublimation drying and analytical drying shown in the table below, specifically:

[0025] After freeze-drying is completed, nitrogen is filled in and the box is plugged. When the temperature and humidity of the environment meet the requirements, the freeze-drying box door is opened and the product is transported to the capping track for aseptic capping.

[0026] Comparative Example 1: The preparation method of the recombinant thiol streptavidin lyophilized powder of this comparative example is: According to the commonly used freeze-drying system on the market, the protective effect of protein protectants (HEPES, TCEP and trehalose) on recombinant thiol streptavidin lyophilized powder was explored. The object of investigation for designing the freeze-dried preparation is sodium phosphate salt, specifically sodium dihydrogen phosphate and disodium hydrogen phosphate. Add recombinant thiol streptavidin stock solution to the vial so that the core streptavidin in each bottle is 10 mg. The concentration of recombinant thiol streptavidin in the stock solution is 10 mg / mL, and the buffer is 5 mM sodium phosphate salt (pH 7.0), which does not contain HEPES, TCEP and trehalose. The setting of the subsequent freeze-drying procedure is exactly the same as that in Example 1.

[0027] The recombinant thiol streptavidin lyophilized powder obtained after treatment in Example 1 and Comparative Example 1 was subjected to a simulated summer transportation test, and related substances were detected before and after. The detection of related substances included solution clarity, protein purity, tetramer percentage, and protein activity. The specific detection method is as follows:

[0028] Simulated summer transport test: Place the sample at 80℃ for 9 hours, then at 40℃ for 15 hours, and repeat this process for a total of 72 hours. Test at the 72nd hour.

[0029] Solution clarity: Take the test sample and add pure water to make a solution containing approximately 10 mg of protein per 1 mL. Test the clarity of the solution according to Method 0902, Part IV of the Pharmacopoeia of the People's Republic of China (2020 edition).

[0030] The results of the solution clarity test are shown in Figure 2 Neutralization Figure 6 ,from Figure 2 and Figure 6 It can be seen that after the sample of Comparative Example 1 was transported in simulated summer, the solution became turbid, while after the sample of Example 1 was transported in simulated summer, the solution was stable.

[0031] Protein purity: After diluting the test sample to 1 mg / mL with pure water, the monomer of recombinant mercaptostreptomycin was identified by reduced SDS-polyacrylamide gel electrophoresis according to the fifth method of 0541 of the fourth general rule of the Pharmacopoeia of the People's Republic of China (2020 edition). The gel concentration of the separation gel was 15%, and the sample amount should not be less than 5 μg (Coomassie Brilliant Blue R250 staining method). After scanning with a scanner, the purity should be no less than 95.0%.

[0032] Tetramer percentage: After diluting the test sample to 1 mg / mL with pure water, the tetramer of recombinant mercaptostreptomycin was identified by non-reduced SDS-polyacrylamide gel electrophoresis according to Method 5 of Part IV General Rules 0541 of the Pharmacopoeia of the People's Republic of China (2020 edition). The gel concentration of the separation gel was 12%, and the sample loading should not be less than 5 μg (Coomassie Brilliant Blue R250 staining method). After scanning with a scanner, the purity should not be less than 95.0%.

[0033] Protein activity: After diluting the test sample to 1 mg / mL with pure water, the activity of core streptavidin (ability to bind biotin) was detected using the Green modified method.

[0034] For specific results, see Figure 3 (a) Figure 3 (b) Figure 4 (a) Figure 4 (b) Figure 5 and Figure 7 (a) Figure 7 (b) Figure 8 (a) Figure 8 (b) Fig. 9 The protein purity of Example 1 after freeze-drying was high, without obvious impurities, and all of them could form good tetramers; after simulated summer transportation, the protein purity was always good, and it could form good tetramers, and there was no obvious difference in protein activity. However, the protein of Comparative Example 1 after freeze-drying had impurities to a certain extent, and after simulated summer transportation, the activity decreased significantly; the tetramer content decreased significantly, indicating that it formed high polymers.

[0035] Example 2 Add recombinant thiol streptavidin stock solution to the vial, so that each vial contains 10 mg of core streptavidin. The concentration of recombinant thiol streptavidin in the stock solution is 5 mg / mL, and the concentrations of HEPES and TCEP are both 20 mM. Then add the prepared trehalose mother solution, so that the final concentration of trehalose is 1.5%. Gently shake the vial to mix the above mixed solution thoroughly.

[0036] The freeze drying procedure is carried out according to pre-freezing, sublimation drying and analytical drying, specifically:

[0037] After freeze-drying is completed, nitrogen is filled in and the box is plugged. When the temperature and humidity of the environment meet the requirements, the freeze-drying box door is opened and the product is transported to the capping track for aseptic capping.

[0038] Example 3 Add recombinant thiol streptavidin stock solution to the vial, so that each vial contains 8 mg of core streptavidin. The concentration of recombinant thiol streptavidin in the stock solution is 5 mg / mL, and the concentrations of HEPES and TCEP are both 20 mM. Then add the prepared trehalose mother solution to make the final concentration of trehalose 1.5%. Gently shake the vial to mix the above mixed solution thoroughly.

[0039] The freeze drying procedure is carried out according to pre-freezing, sublimation drying and analytical drying, specifically:

[0040] After freeze-drying is completed, nitrogen is filled in and the box is plugged. When the temperature and humidity of the environment meet the requirements, the freeze-drying box door is opened and the product is transported to the capping track for aseptic capping.

[0041] The recombinant thiol streptavidin lyophilized powder obtained after the treatment of Example 2-3 was subjected to a simulated summer transportation test, and the related substances before and after were detected according to the detection method in Example 1. The structure showed that the protein purity of the two lyophilized powders was about 98%, without obvious impurities, and both could form good tetramers, with a tetramer percentage of about 99%; after simulated summer transportation, the solution was stored stably, the protein purity was always good, maintained at about 98%, and there was no significant difference in tetramer content and protein activity before simulated summer transportation.

[0042] The above embodiments describe in detail the structure, features and effects of the present invention. The above are only preferred embodiments of the present invention. Any changes made in accordance with the concept of the present invention, or modifications to equivalent embodiments with equivalent changes, which do not exceed the scope covered by the specification, should be within the protection scope of the present invention.

Claims

1. A method for preparing a recombinant thiol streptavidin lyophilized powder, characterized in that: The following steps are involved: (1) adding trehalose to a mixed solution of recombinant thiol streptavidin stock solution, TCEP, and HEPES, and controlling the pH value of the mixed solution to be 6.5-7.5; the concentration of the recombinant thiol streptavidin is 5-10 mg / ml, the concentration of TCEP is 20 mM, the concentration of HEPES is 20 mM, and the mass fraction of trehalose is 1.5%; (2) freeze-drying the mixed liquid; freeze-drying includes three stages: pre-freezing, sublimation drying and analytical drying, and the specific operating conditions are as follows: the temperature of the pre-freezing stage is set at -50~-20°C, and the holding time is 60 to 300 minutes; the temperature of the sublimation drying stage is set at -40~10°C, and the holding time is 300 to 1500 minutes, and the vacuum degree is 0 to 0.5 mbar; the temperature of the analytical drying stage is set at -20~20°C, and the holding time is 60 to 600 minutes, and the vacuum degree is 0 to 0.01 mbar.

2. The preparation method according to claim 1, characterized in that: The pH value in step (1) is 7.

0.

3. The preparation method according to claim 1, characterized in that: It takes 20 to 60 minutes to adjust from room temperature to the target temperature of the pre-freezing stage, then 20 to 60 minutes to adjust to the target temperature of the sublimation drying stage, and finally 30 to 300 minutes to adjust to the target temperature of the analytical drying stage.

4. The recombinant thiol-streptavidin lyophilized powder prepared by the method according to any one of claims 1 to 3.

5. A solution based on recombinant thiostreptavidin lyophilized powder, comprising the recombinant thiostreptavidin lyophilized powder according to claim 4 and a solvent.

6. The solution according to claim 5, characterized in that The solvent is pure water, and the usage ratio of pure water to the recombinant thiol streptavidin lyophilized powder is 1 mL:10 mg.

7. Use of the recombinant mercaptostreptavidin lyophilized powder as claimed in claim 4 in the separation, detection and labeling of biological molecules.

Citation Information

Patent Citations

  • Streptavidin containing long-chain sulfydryl arm and preparation method thereof

    CN115215927A

  • Preparation method and detection method of core streptavidin freeze-dried powder

    CN117442567A

  • Multimer composition of capsule protein and pharmaceutical composition using the same

    JP2021088518A